Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans

Hassan Ashktorab, Duane T. Smoot, Haleh Farzanmehr, Marie Fidelia-Lambert, Bahram Momen, Linda Hylind, Christine Iacosozio-Dononue, John M. Carethers, Ajay Goel, C. Richard Boland, Francis M Giardiello

Research output: Contribution to journalArticle

Abstract

African Americans (AAs) have a 1.5 times higher risk of colorectal carcinoma (CRC) than Caucasians. Gene silencing through CpG island hypermethylation has been associated with the genesis or progression of microsatellite instability (MSI) largely due to 1 target for hypermethylation being the DNA mismatch repair gene hMLH1; there is anecdotal evidence of an increased incidence of MSI among AAs. P16 and hMLH1 can be inactivated by hypermethylation of their respective promoter regions, abrogating the ability to regulate cell proliferation and repair processes. We studied such methylation, as well as hMHS2 expression in colorectal cancers from AA patients to determine if MSI is associated with epigenetic silencing. Experiments were conducted on matched normal and colon cancer tissues from AA patients (n = 51). A total of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25 and BAT26) were used to evaluate MSI status. P16 and hMLH1 promoter methylation status was determined following bisulfite modification of DNA and using methylation specific PCR, while immunohistochemistry (IHC) was used to examine expression of hMLH1 and hMSH2. A total of 22 (43%) cancers demonstrated microsatellite instability-high (MSI-H), while 27 were microsatellite stable (MSS) and 2 were microsatellite instability-low (MSH-L). Most of the MSI-H tumors were proximal, well differentiated and highly mucinous. Most patients in the MSI-H group were females (68%). The p16 promoter was methylated in 19 of 47 (40%) tumors. A total of 7 of these CRCs demonstrated MSI-H (33%). The hMLH1 promoter was methylated in 29 of 34 (85%) tumors, of which 13 CRCs demonstrated MSI-H (87%). hMLH1 and hMSH2 staining was observed in 66% and 38% of MSI-H tumors, respectively. Overall, the prevalence of MSI-H colorectal tumor was 2-3-fold higher, while the defect in the percentage expression of mismatch repair (MMR) genes (hMLH1 and hMSH2) was similar in AA patients compared to the U.S. Caucasian population. Similar numbers of AA MSS tumors with p16 and hMLH1 methylation likely indicate hemimethylation of genes that might reflect environmental or genetic influences that might be more common in the AA population.

Original languageEnglish (US)
Pages (from-to)914-919
Number of pages6
JournalInternational Journal of Cancer
Volume116
Issue number6
DOIs
StatePublished - Oct 10 2005

Fingerprint

Microsatellite Instability
African Americans
Colorectal Neoplasms
Microsatellite Repeats
Methylation
Neoplasms
DNA Mismatch Repair
Genes
Melanocyte-Stimulating Hormones
CpG Islands
Gene Silencing
DNA Methylation
Genetic Promoter Regions
Epigenomics
Colonic Neoplasms
Population
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. / Ashktorab, Hassan; Smoot, Duane T.; Farzanmehr, Haleh; Fidelia-Lambert, Marie; Momen, Bahram; Hylind, Linda; Iacosozio-Dononue, Christine; Carethers, John M.; Goel, Ajay; Boland, C. Richard; Giardiello, Francis M.

In: International Journal of Cancer, Vol. 116, No. 6, 10.10.2005, p. 914-919.

Research output: Contribution to journalArticle

Ashktorab, H, Smoot, DT, Farzanmehr, H, Fidelia-Lambert, M, Momen, B, Hylind, L, Iacosozio-Dononue, C, Carethers, JM, Goel, A, Boland, CR & Giardiello, FM 2005, 'Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans', International Journal of Cancer, vol. 116, no. 6, pp. 914-919. https://doi.org/10.1002/ijc.21062
Ashktorab, Hassan ; Smoot, Duane T. ; Farzanmehr, Haleh ; Fidelia-Lambert, Marie ; Momen, Bahram ; Hylind, Linda ; Iacosozio-Dononue, Christine ; Carethers, John M. ; Goel, Ajay ; Boland, C. Richard ; Giardiello, Francis M. / Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. In: International Journal of Cancer. 2005 ; Vol. 116, No. 6. pp. 914-919.
@article{84134e38fddf4848bf86c7ce7f64468d,
title = "Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans",
abstract = "African Americans (AAs) have a 1.5 times higher risk of colorectal carcinoma (CRC) than Caucasians. Gene silencing through CpG island hypermethylation has been associated with the genesis or progression of microsatellite instability (MSI) largely due to 1 target for hypermethylation being the DNA mismatch repair gene hMLH1; there is anecdotal evidence of an increased incidence of MSI among AAs. P16 and hMLH1 can be inactivated by hypermethylation of their respective promoter regions, abrogating the ability to regulate cell proliferation and repair processes. We studied such methylation, as well as hMHS2 expression in colorectal cancers from AA patients to determine if MSI is associated with epigenetic silencing. Experiments were conducted on matched normal and colon cancer tissues from AA patients (n = 51). A total of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25 and BAT26) were used to evaluate MSI status. P16 and hMLH1 promoter methylation status was determined following bisulfite modification of DNA and using methylation specific PCR, while immunohistochemistry (IHC) was used to examine expression of hMLH1 and hMSH2. A total of 22 (43{\%}) cancers demonstrated microsatellite instability-high (MSI-H), while 27 were microsatellite stable (MSS) and 2 were microsatellite instability-low (MSH-L). Most of the MSI-H tumors were proximal, well differentiated and highly mucinous. Most patients in the MSI-H group were females (68{\%}). The p16 promoter was methylated in 19 of 47 (40{\%}) tumors. A total of 7 of these CRCs demonstrated MSI-H (33{\%}). The hMLH1 promoter was methylated in 29 of 34 (85{\%}) tumors, of which 13 CRCs demonstrated MSI-H (87{\%}). hMLH1 and hMSH2 staining was observed in 66{\%} and 38{\%} of MSI-H tumors, respectively. Overall, the prevalence of MSI-H colorectal tumor was 2-3-fold higher, while the defect in the percentage expression of mismatch repair (MMR) genes (hMLH1 and hMSH2) was similar in AA patients compared to the U.S. Caucasian population. Similar numbers of AA MSS tumors with p16 and hMLH1 methylation likely indicate hemimethylation of genes that might reflect environmental or genetic influences that might be more common in the AA population.",
author = "Hassan Ashktorab and Smoot, {Duane T.} and Haleh Farzanmehr and Marie Fidelia-Lambert and Bahram Momen and Linda Hylind and Christine Iacosozio-Dononue and Carethers, {John M.} and Ajay Goel and Boland, {C. Richard} and Giardiello, {Francis M}",
year = "2005",
month = "10",
day = "10",
doi = "10.1002/ijc.21062",
language = "English (US)",
volume = "116",
pages = "914--919",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans

AU - Ashktorab, Hassan

AU - Smoot, Duane T.

AU - Farzanmehr, Haleh

AU - Fidelia-Lambert, Marie

AU - Momen, Bahram

AU - Hylind, Linda

AU - Iacosozio-Dononue, Christine

AU - Carethers, John M.

AU - Goel, Ajay

AU - Boland, C. Richard

AU - Giardiello, Francis M

PY - 2005/10/10

Y1 - 2005/10/10

N2 - African Americans (AAs) have a 1.5 times higher risk of colorectal carcinoma (CRC) than Caucasians. Gene silencing through CpG island hypermethylation has been associated with the genesis or progression of microsatellite instability (MSI) largely due to 1 target for hypermethylation being the DNA mismatch repair gene hMLH1; there is anecdotal evidence of an increased incidence of MSI among AAs. P16 and hMLH1 can be inactivated by hypermethylation of their respective promoter regions, abrogating the ability to regulate cell proliferation and repair processes. We studied such methylation, as well as hMHS2 expression in colorectal cancers from AA patients to determine if MSI is associated with epigenetic silencing. Experiments were conducted on matched normal and colon cancer tissues from AA patients (n = 51). A total of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25 and BAT26) were used to evaluate MSI status. P16 and hMLH1 promoter methylation status was determined following bisulfite modification of DNA and using methylation specific PCR, while immunohistochemistry (IHC) was used to examine expression of hMLH1 and hMSH2. A total of 22 (43%) cancers demonstrated microsatellite instability-high (MSI-H), while 27 were microsatellite stable (MSS) and 2 were microsatellite instability-low (MSH-L). Most of the MSI-H tumors were proximal, well differentiated and highly mucinous. Most patients in the MSI-H group were females (68%). The p16 promoter was methylated in 19 of 47 (40%) tumors. A total of 7 of these CRCs demonstrated MSI-H (33%). The hMLH1 promoter was methylated in 29 of 34 (85%) tumors, of which 13 CRCs demonstrated MSI-H (87%). hMLH1 and hMSH2 staining was observed in 66% and 38% of MSI-H tumors, respectively. Overall, the prevalence of MSI-H colorectal tumor was 2-3-fold higher, while the defect in the percentage expression of mismatch repair (MMR) genes (hMLH1 and hMSH2) was similar in AA patients compared to the U.S. Caucasian population. Similar numbers of AA MSS tumors with p16 and hMLH1 methylation likely indicate hemimethylation of genes that might reflect environmental or genetic influences that might be more common in the AA population.

AB - African Americans (AAs) have a 1.5 times higher risk of colorectal carcinoma (CRC) than Caucasians. Gene silencing through CpG island hypermethylation has been associated with the genesis or progression of microsatellite instability (MSI) largely due to 1 target for hypermethylation being the DNA mismatch repair gene hMLH1; there is anecdotal evidence of an increased incidence of MSI among AAs. P16 and hMLH1 can be inactivated by hypermethylation of their respective promoter regions, abrogating the ability to regulate cell proliferation and repair processes. We studied such methylation, as well as hMHS2 expression in colorectal cancers from AA patients to determine if MSI is associated with epigenetic silencing. Experiments were conducted on matched normal and colon cancer tissues from AA patients (n = 51). A total of 5 microsatellite markers (D2S123, D5S346, D17S250, BAT25 and BAT26) were used to evaluate MSI status. P16 and hMLH1 promoter methylation status was determined following bisulfite modification of DNA and using methylation specific PCR, while immunohistochemistry (IHC) was used to examine expression of hMLH1 and hMSH2. A total of 22 (43%) cancers demonstrated microsatellite instability-high (MSI-H), while 27 were microsatellite stable (MSS) and 2 were microsatellite instability-low (MSH-L). Most of the MSI-H tumors were proximal, well differentiated and highly mucinous. Most patients in the MSI-H group were females (68%). The p16 promoter was methylated in 19 of 47 (40%) tumors. A total of 7 of these CRCs demonstrated MSI-H (33%). The hMLH1 promoter was methylated in 29 of 34 (85%) tumors, of which 13 CRCs demonstrated MSI-H (87%). hMLH1 and hMSH2 staining was observed in 66% and 38% of MSI-H tumors, respectively. Overall, the prevalence of MSI-H colorectal tumor was 2-3-fold higher, while the defect in the percentage expression of mismatch repair (MMR) genes (hMLH1 and hMSH2) was similar in AA patients compared to the U.S. Caucasian population. Similar numbers of AA MSS tumors with p16 and hMLH1 methylation likely indicate hemimethylation of genes that might reflect environmental or genetic influences that might be more common in the AA population.

UR - http://www.scopus.com/inward/record.url?scp=23944502764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944502764&partnerID=8YFLogxK

U2 - 10.1002/ijc.21062

DO - 10.1002/ijc.21062

M3 - Article

C2 - 15856472

AN - SCOPUS:23944502764

VL - 116

SP - 914

EP - 919

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -